GW Pharmaceuticals — Shareholder Meeting (June 2019)
28 slides from GW Pharmaceuticals's shareholder meeting presentation, Jun 13, 2019
Slide 1: Annual General Meeting June 13, 2019
©2019 GW Pharmaceuticals. All rights reserved. NASDAQ: GWPH Grace Living with Dravet syndrome, Being treated with Epidiolex ® Annual General Meeting June 13, 2019
Slide 2: Forward-Looking Statements
This presentation contains forward - looking statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward - looking statements include information about our current expectations for future events, including potential results of o
Slide 3: Recent Highlights
Recent Highlights JUNE 13, 2019 3 • Epidiolex ® (CBD) • U.S. launched November 1 st 2018 • Q1 19 net sales - $33.5m • EU regulatory submission under review – CHMP opinion expected mid - year • Commercial team in place in 5 major European markets • Clinical • Positive results in second Phase 3 Dravet
Slide 4: U.S. Commercial Update
Lily Living with Dravet syndrome, Being treated with Epidiolex ® U.S. Commercial Update
Slide 5: FDA Approves First Medicine Derived From Cannabis Plant
FDA Approves First Medicine Derived From Cannabis Plant JUNE 13, 2019 5
Slide 6: Statement By FDA Commissioner Scott Gottlieb, MD
Statement By FDA Commissioner, Scott Gottlieb, MD JUNE 13, 2019 6 “Sound scientific research to investigate ingredients derived from marijuana can lead to important therapies. This new treatment provides new options for patients. Because of this careful, scientific and evidence - based evaluation by
Slide 7: US Commercial Organization
US Commercial Organization Darren Cline US Chief Commercial Officer VP, US Public Policy & Public Affairs Sr. Director, US Pricing and Trade VP, US Sales VP, US Market Access VP, US Medical Affairs VP, US Marketing Director, US Business Analytics & Sales Operations 4 Professionals 12 Professionals T
Slide 8: Epidiolex Launch Drivers
Epidiolex ® Launch Drivers No new treatments for LGS since 2011 First FDA approved and available treatment for Dravet syndrome High awareness of CBD PATIENT DEMAND Significant interest/need for clinicians to understand Epidiolex ® science and data Differentiation from unregulated CBD CLINICIAN EDUCA
Slide 9: Educating HCPs Through an Extensive Educational and Speaker Program
• Additional disease education highlighting key difficulties in diagnosing LGS and Dravet syndrome, and identifying how symptoms may vary and evolve over time • Currently have 77 trained speakers with 213 total speaker events completed 2019 • 1240 HCP Attendees Educating HCPs Through an Extensive Ed
Slide 10: Supporting the Patient Experience
Supporting the Patient Experience JUNE 13, 2019 10
Slide 11: Q1 2019 Results Highlights
Q1 2019 Results Highlights Physician Reach ▪ Q1 Net Sales of $33.5M ▪ 7,600+ patients have received Epidiolex prescriptions since launch ▪ 1,900+ physicians have dispensed prescriptions since launch ▪ Pharmacy distribution network includes 145+ distribution points ▪ Approximately 75% of 900 patients
Slide 12: Impact of Epidiolex on Patient Lives
“Today, Jacqueline received a call from a mother/caregiver requesting – through tears – that we give a BIG Thank You to all involved with the Epidiolex Program! She shared: “This is the most hope I’ve had for my daughter in years!” JUNE 13, 2019 12 Impact of Epidiolex on Patient Lives
Slide 13: Europe Launch Preparations
Arlo Living with Dravet syndrome Europe Launch Preparations
Slide 14: EU Launch Update: Epidyolex
EU Launch Update: Epidyolex ® JUNE 13, 2019 14 ▪ Positive CHMP opinion expected mid - year ▪ Commercial organization now almost fully in place for the first wave 5 major European markets ▪ Sales professionals have been recruited in France & Germany ▪ Field - based team comprised of 17 MSLs, Country
Slide 15: Pipeline Update
Jon Living with Lennox - Gastaut syndrome Being treated with Epidiolex ® Pipeline Update
Slide 16: Epidiolex Phase 3 TSC Trial Overview
▪ Phase 3, randomized double - blind placebo - controlled trial in patients with treatment - resistant Tuberous Sclerosis Complex (TSC) ▪ TSC is a rare genetic condition that causes tumors to grow in many different organs of the body ▪ Enrollment: 224 patients into three arms, where EPIDIOLEX 25 mg/
Slide 17: Primary Efficacy Measure: Change in TSC-Associated Seizures
Primary Efficacy Measure: Change in Number of TSC - Associated Seizures During Treatment Period Compared to Baseline 0 10 20 30 40 50 60 Treatment PLB (n=76) CBD25 (n=75) CBD50 (n=73) p=0.0018 p=0.0009 % reduction in seizures JUNE 13, 2019 17
Slide 18: TSC Phase 3 Trial Safety
▪ The safety profile observed is consistent with findings from previous studies, with no new safety risks identified ▪ There is a lower incidence of known adverse events and laboratory changes in the 25 mg/kg/day group compared with 50 mg/kg/day ▪ Given that both doses studied have been shown to be
Slide 19: Offering Hope to a New Patient Population
▪ sNDA submission expected Q4 19 ▪ TSC affects 40,000 - 80,000 individuals in the U.S. and about 1 to 2 million individuals worldwide ▪ Epilepsy is present in greater than 90% of patients with TSC ▪ More than 60% of individuals with TSC and epilepsy do not achieve seizure control with standard treat
Slide 20: Sativex in the United States
• Approved in >25 countries outside of the U.S. for the treatment of spasticity due to multiple sclerosis (MS); sold via marketing partners • Three positive Phase 3 trials completed in Europe • US development and commercial rights recovered from Otsuka, and now wholly owned by GW • U.S. development
Slide 21: GW's Cannabinoid Platform: A Proprietary Growth Engine Beyond Epidiolex
The most common AEs that occurred in the CBD - treated patients were somnolence, decreased appetite, diarrhea, pyrexia, convulsion, and fatigue. GW’s Cannabinoid Platform: A Proprietary Growth Engine Beyond Epidiolex ® JANUARY 8, 2019 21 PRE - CLINICAL PHASE 1 PHASE 2 PHASE 3 SUBMIT FDA - APPROVED E
Slide 22: Financial Overview
Poppy Living with Dravet syndrome Financial Overview Scott Giacobello Chief Financial Officer
Slide 23: Q1 2019 Results
Q1 2019 Results Q1 19 Epidiolex Revenue $34.7M (US $33.5M) Total Revenue $39M Total Operating Expenses (as Reported incl. Cost of Sales) $91M Cash Balance – As of 31 Mar 2019 $522M Net Cash Outflow excl. Fundraising - $70M JUNE 13, 2019 23
Slide 24: Key Financial Data
Key Financial Data JUNE 13, 2019 24 Cash at March 31, 2019 $521.7m Cash from PRV sale in April, 2019 $105m FY 2019 operating expense guidance FY 2019 capital expense guidance $395m – $425m $30m - $40m Share Capital Current Options Fully Diluted ADS/m 30.6 1.2 31.8
Slide 25: Looking Forward
Iwan Living with Dravet syndrome Looking Forward Justin Gover
Slide 26: 2019 Key Milestones
2019 Key Milestones 26 JUNE 13, 2019 EPIDIOLEX ® COMMERCIAL U.S. sales updates Quarterly European launches Q3 2019 onwards EPIDIOLEX ® R&D EMA CHMP opinion Mid - 2019 TSC data presentation Q4 2019 Rett syndrome Phase 3 study start Q2 2019 TSC FDA sNDA submission Q4 2019 EPIDIOLEX ® LIFE CYCLE Use/fo
Slide 27: and never losing focus on what matters most … our patients
and never losing focus on what matters most … our patients
Slide 28: Thank You
Iwan Living with Dravet syndrome Thank You GW Pharmaceuticals plc NASDAQ: GWPH Stephen Schultz VP Investor Relations sschultz@gwpharm.com 917 - 280 - 2424 401 - 500 - 6570